Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KRAS | P01116 | 20/20 | 0.82 |
| ▸ | VHL | P40337 | 1/20 | 0.63 |
| ▸ | CDK7 | P50613 | 1/20 | 0.63 |
| ▸ | CCNH | P51946 | 1/20 | 0.63 |
| ▸ | MNAT1 | P51948 | 1/20 | 0.63 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23668485 | 1.00 | KRAS (0.82) | KRASVHLCDK7CCNHMNAT1 | |
| SCHEMBL30188761 | 0.97 | KRAS (0.87) | KRASVHLCDK7CCNHMNAT1 | |
| SCHEMBL19636743 | 0.97 | KRAS (0.87) | KRASVHLCDK7CCNHMNAT1 | |
| SCHEMBL21786250 | 0.94 | KRAS (0.84) | KRASSOS1 | |
| SCHEMBL21786403 | 0.94 | KRAS (0.84) | KRASSOS1 | |
| SCHEMBL23074761 | 0.94 | KRAS (0.78) | KRASVHLCDK7CCNHMNAT1 | |
| SCHEMBL23668482 | 0.94 | KRAS (0.84) | KRASSOS1 | |
| SCHEMBL23074857 | 0.94 | KRAS (0.80) | KRASVHLCDK7CCNHMNAT1 | |
| SCHEMBL21786255 | 0.93 | KRAS (0.79) | KRASVHLCDK7CCNHMNAT1 | |
| SCHEMBL23074919 | 0.93 | KRAS (0.85) | KRASVHLCDK7CCNHMNAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3844151-B1 | KRAS G12C INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2023-08-23 | — | — | EP | disclosed |
| US-20210230170-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. | 2021-07-29 | — | — | US | disclosed |
| WO-2021043322-A1 | AZEPINO PYRIMIDINE DERIVATIVES AND MEDICAL USE THEREOF | 正大天晴药业集团南京顺欣制药有限公司 | 2021-03-11 | — | — | WO | disclosed |
| WO-2020047192-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. (US) | 2020-03-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210230170-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | KRAS 1/4885VHL 4/4885CDK7 234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.